Natural Products From Plants Targeting Leptin Resistance for the Future Development of Anti-Obesity Agents
Abstract
Obesity is a serious health threat, which has affected 16% of adults globally in 2022 and shows a trend toward youthfulness. Leptin, as a regulator of body weight, can suppress appetite and promote energy expenditure, making it potential in obesity treatment. Nevertheless, with the progress of relevant research, it is worth noting that monotherapy with leptin is not an effective strategy since most obese individuals are hyperleptinemic and resistant to leptin, where high levels of leptin fail to exert its weight-loss effects. Therefore, the potential to unlock the weight-loss properties of leptin using pharmacology to improve resistance has provided a new direction for this field. However, most synthetic medicines have retreated from the market due to their undesirable side effects, while natural products are increasingly sought after for drug development due to their minimal side effects. Indeed, natural products are ideal alternatives to oral synthetic agents since a growing body of research has demonstrated their desirable effects on improving leptin resistance through potential therapeutic targets like the JAK2/STAT3 signaling pathway, protein tyrosine phosphatase 1B, the exchange proteins directly activated by cAMP/Ras-related protein 1 signaling pathway, endoplasmic reticulum stress, pro-opiomelanocortin gene, and leptin levels. This review outlines natural products that can improve leptin resistance by inhibiting or activating these targets and evaluates their efficacy in experiments and human clinical trials, offering insights for the development of anti-obesity agents. However, more high-quality clinical research is necessary to validate these findings, as current clinical evidence is constrained by heterogeneity and small sample sizes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The JAK2/STAT3 pathway is essential for the anorexigenic effect of leptin by stimulating POMC expression and inhibiting NPY.
“The JAK2/STAT3 pathway is essential for the anorexigenic effect of leptin by stimulating the expression of pro-opiomelanocortin (POMC) and inhibiting NPY”
From Exercise-Induced Muscle–Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging (2025) · cites this paper as [82]
The citation lists haven’t been fetched yet
References 140 · Cited by 6
- Authors
- Liu, Y., & Gong, F.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Gong, Fengying
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2025-01-04
- Volume
- 39
- Issue
- 2
- Pages
- 1174-1189
- ISSN
- 0951-418X (ISSN-L)
- 1099-1573
- OpenAlex
- W4406061038
- Cited by
- 6
- References
- 140
- Citations by year
- 2026: 2 · 2025: 4
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Phytotherapy Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82270913)
- Natural Science Foundation of Beijing Municipality (7222137)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- leptin resistance, obesity, anti-obesity drugs, natural products, JAK2/STAT3 signaling, PTP1B, ERK signaling, endoplasmic reticulum stress, proopiomelanocortin, hyperleptinemia, plant extracts
- MeSH terms
- Animals, Biological Products, Drug Resistance, Humans, Obesity, Signal Transduction, Anti-Obesity Agents, Leptin, STAT3 Transcription Factor, Janus Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review